SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-013376
Filing Date
2020-11-09
Accepted
2020-11-09 16:24:41
Documents
77
Period of Report
2020-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q cara-20200930x10q.htm   iXBRL 10-Q 2523831
2 EX-31.1 cara-20200930xex31d1.htm EX-31.1 12197
3 EX-31.2 cara-20200930xex31d2.htm EX-31.2 11870
4 EX-32.1 cara-20200930xex32d1.htm EX-32.1 10195
  Complete submission text file 0001558370-20-013376.txt   9634546

Data Files

Seq Description Document Type Size
5 EX-101.SCH cara-20200930.xsd EX-101.SCH 58334
6 EX-101.CAL cara-20200930_cal.xml EX-101.CAL 61246
7 EX-101.DEF cara-20200930_def.xml EX-101.DEF 293315
8 EX-101.LAB cara-20200930_lab.xml EX-101.LAB 546935
9 EX-101.PRE cara-20200930_pre.xml EX-101.PRE 485794
10 EXTRACTED XBRL INSTANCE DOCUMENT cara-20200930x10q_htm.xml XML 1683146
Mailing Address 4 STAMFORD PLAZA 107 ELM STREET 9TH FLOOR STAMFORD CT 06902
Business Address 4 STAMFORD PLAZA 107 ELM STREET 9TH FLOOR STAMFORD CT 06902 203-406-3700
Cara Therapeutics, Inc. (Filer) CIK: 0001346830 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36279 | Film No.: 201298056
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences